SHANGHAI, CHINA--(MARKET WIRE)--Aug 21, 2007 -- Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTC BB:SOBM.OB - News) is pleased to update on preclinical trial progress for the recombinant human kallikrein (rhK1) being developed by Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing"), the Company's 82% owned subsidiary.
